Valeant CEO Outlines Takeover Rationale, As Cephalon Stays Mum
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant doesn't want a protracted proxy fight and is prepared to drop its offer if Cephalon shareholders object - even as Wall Street reacts favorably.
You may also be interested in...
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
The giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
The giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.
Teva Swoops In To Snatch Cephalon For $6.7 Billion
Cephalon, the mid-sized specialty pharma company has found a white knight. Just two weeks before a May 12 deadline required shareholders to tender their shares for or against a takeover offer by Valeant Pharmaceuticals International, the company has accepted a $6.8 billion cash offer from Teva Pharmaceutical Industries.